Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 22/01/2026 am IST			Pre-market 04:47:29 pm
49.81 ^USD	+15.84%		52.10	+4.60%

11:33am	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE
22/01	US Equity Markets Rise After Trump Rules Out Using Force in Greenland Bid	MT

Moderna, Inc.(NasdaqGS:MRNA) added to Russell Midcap Value Index

Published on 07/01/2025 at 02:36 am IST

S&P Capital IQ

MODERNA, INC.

+15.84%

Moderna, Inc.(NasdaqGS:MRNA) added to Russell Midcap Value Index

Latest news about Moderna, Inc.

11:33am	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE
22/01	US Equity Markets Rise After Trump Rules Out Using Force in Greenland Bid	MT
21/01	Health Care Down, But not by Much, on Defensive Bias - Health Care Roundup	DJ
20/01	Wall Street in turn is hit by Trump's threats
20/01	Moderna and Merck confirm the lasting effectiveness of their skin cancer vaccine
20/01	Moderna, Merck's Skin Cancer Therapy Shows 49% Lower Risk of Cancer in Mid-Stage Study	MT
20/01	Correction to Moderna, Merck Cancer-Vaccine Story	DJ
20/01	Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up	RE
20/01	Moderna, Merck Report Positive Results From Cancer-Vaccine Study	DJ
20/01	Moderna, Merck's skin cancer vaccine shows sustained benefit after five years	RE
20/01	Moderna says Keytruda combo shows sustained 5-yr improvement in main goal for cancer vaccine	RE
17/01	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
17/01	Sector Update: Health Care Stocks Softer Friday Afternoon	MT
16/01	Sector Update: Health Care	MT
16/01	Arbutus Biopharma Says European Patent Office Revokes Patent; Shares Fall	MT
16/01	Arbutus Biopharma Corp - EPO revokes Arbutus Biopharma's European patent EP 2279254 - SEC filing	RE
14/01	US Equity Markets Fall as Investors Weigh Bank Earnings, December Inflation Data	MT
13/01	PRESS DIGEST- Financial Times - January 13	RE
13/01	Moderna, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 04:30 PM
13/01	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
13/01	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT
12/01	Sector Update: Health Care	MT
12/01	Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating	MT
12/01	Moderna Sees 2025 Revenue Close to Outlook Range, Affirms Growth Target For This Year	MT
12/01	Moderna Expects 2025 Revenue of $1.9 Billion	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

13/02 - Q4 2025 Earnings Release

More about the company